Table of Contents

1. Altmetric Badge
   Book Overview
2. Altmetric Badge
   Chapter 1 Anti-oxidants and cognitive function: a review of clinical and epidemiologic studies
3. Altmetric Badge
   Chapter 2 Brain abnormalities in the elderly: frequency and predictors in the United States (the Cardiovascular Health Study)
4. Altmetric Badge
   Chapter 3 Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam study
5. Altmetric Badge
   Chapter 4 The spectrum of age-associated brain abnormalities: their measurement and histopathological correlates
6. Altmetric Badge
   Chapter 5 Cognitive correlates of cerebral white matter changes
7. Altmetric Badge
   Chapter 6 Concepts on the prognostic significance of white matter changes
8. Altmetric Badge
   Chapter 7 Difficulties in the clinical diagnosis of vascular dementia and dementia of the Alzheimer type — comparison of clinical classifications
9. Altmetric Badge
   Chapter 8 Problems of differential diagnosis between depressive pseudodementia and Alzheimer’s disease
10. Altmetric Badge
    Chapter 9 The neuropathological diagnosis of Alzheimer disease
11. Altmetric Badge
    Chapter 10 The progression of the lesions in Alzheimer disease: insights from a prospective clinicopathological study
12. Altmetric Badge
    Chapter 11 Evolution of neuronal changes in the course of Alzheimer’s disease
13. Altmetric Badge
    Chapter 12 The cytoskeleton in Alzheimer disease
14. Altmetric Badge
    Chapter 13 Mechanisms of synaptic pathology in Alzheimer’s disease
15. Altmetric Badge
    Chapter 14 Proteolytic processing of Alzheimer’s disease associated proteins
16. Altmetric Badge
    Chapter 15 Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles
17. Altmetric Badge
    Chapter 16 Presenilins and Alzheimer’s disease: the role of Aβ42
18. Altmetric Badge
    Chapter 17 Biological markers for the diagnosis of Alzheimer’s disease
19. Altmetric Badge
    Chapter 18 Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer’s disease
20. Altmetric Badge
    Chapter 19 Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer’s disease
21. Altmetric Badge
    Chapter 20 Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing
22. Altmetric Badge
    Chapter 21 Positron emission tomography for diagnosis of Alzheimer’s disease and vascular dementia
23. Altmetric Badge
    Chapter 22 Current diagnostic methods and outcome variables for clinical investigation of Alzheimer’s disease
24. Altmetric Badge
    Chapter 23 Perspectives in clinical Alzheimer’s disease research and the development of antidementia drugs
25. Altmetric Badge
    Chapter 24 The role of glutamate in dementia
26. Altmetric Badge
    Chapter 25 Neurotrophic activities and therapeutic experience with a brain derived peptide preparation
27. Altmetric Badge
    Chapter 26 Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats
28. Altmetric Badge
    Chapter 27 The influence of Cerebrolysin® and E021 on spatial navigation of 24-month-old rats
29. Altmetric Badge
    Chapter 28 Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors
30. Altmetric Badge
    Chapter 29 Antioxidant systemic effect of short-term Cerebrolysin® administration
31. Altmetric Badge
    Chapter 30 Can Cerebrolysin® influence chronic deterioration of spatial learning and memory?
32. Altmetric Badge
    Chapter 31 Cerebrolysin® protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia
33. Altmetric Badge
    Chapter 32 Further evidence that Cerebrolysin® protects cortical neurons from neurodegeneration in vitro
34. Altmetric Badge
    Chapter 33 Influence of BDNF and FCS on viability and programmed cell death (PCD) of developing cortical chicken neurons in vitro
35. Altmetric Badge
    Chapter 34 Dose-dependent effects of Cerebrolysin® on EEG and short term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia